• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's After-Market Session

    3/29/24 4:30:47 PM ET
    $APLT
    $BPTS
    $BTMD
    $GRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $APLT alert in real time by email

    Gainers

    • Qilian Intl Hldg Gr (NASDAQ:QLI) shares rose 63.8% to $1.04 during Friday's after-market session. The market value of their outstanding shares is at $37.1 million.
    • Sunshine Biopharma (NASDAQ:SBFM) stock moved upwards by 39.5% to $0.08. The company's market cap stands at $8.3 million.
    • Galera Therapeutics (NASDAQ:GRTX) shares increased by 28.57% to $0.18. The company's market cap stands at $9.7 million. As per the news, the Q4 earnings report came out yesterday.
    • Medpace Hldgs (NASDAQ:MEDP) shares rose 18.76% to $480.0. The market value of their outstanding shares is at $14.7 billion.
    • Xilio Therapeutics (NASDAQ:XLO) shares rose 17.59% to $1.29. The company's market cap stands at $35.5 million.
    • VYNE Therapeutics (NASDAQ:VYNE) shares rose 13.02% to $3.47. The company's market cap stands at $48.9 million.

    Losers

    • Vivos Therapeutics (NASDAQ:VVOS) shares fell 22.4% to $3.75 during Friday's after-market session. The market value of their outstanding shares is at $4.9 million. As per the news, the Q4 earnings report came out yesterday.
    • ENDRA Life Sciences (NASDAQ:NDRA) shares decreased by 19.54% to $0.47. The company's market cap stands at $5.1 million. As per the news, the Q4 earnings report came out yesterday.
    • Applied Therapeutics (NASDAQ:APLT) shares fell 15.15% to $5.77. The company's market cap stands at $610.9 million.
    • Biophytis (NASDAQ:BPTS) shares decreased by 11.43% to $0.31. The company's market cap stands at $3.5 million.
    • Pulse Biosciences (NASDAQ:PLSE) shares fell 10.68% to $7.78. The market value of their outstanding shares is at $428.5 million. As per the press release, Q4 earnings came out yesterday.
    • Biote (NASDAQ:BTMD) stock decreased by 10.18% to $5.21. The market value of their outstanding shares is at $186.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $APLT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APLT
    $BPTS
    $BTMD
    $GRTX

    CompanyDatePrice TargetRatingAnalyst
    Medpace Holdings Inc.
    $MEDP
    3/6/2026$500.00Underweight → Equal Weight
    Barclays
    Medpace Holdings Inc.
    $MEDP
    3/3/2026$522.00Outperform
    RBC Capital Mkts
    Medpace Holdings Inc.
    $MEDP
    2/18/2026$419.00Sell → Hold
    TD Cowen
    Medpace Holdings Inc.
    $MEDP
    2/13/2026$560.00Hold → Buy
    Jefferies
    Medpace Holdings Inc.
    $MEDP
    2/10/2026$564.00Neutral → Outperform
    Robert W. Baird
    Pulse Biosciences Inc
    $PLSE
    1/30/2026$25.00Outperform
    Mizuho
    Applied Therapeutics Inc.
    $APLT
    12/12/2025Outperform → Neutral
    Robert W. Baird
    Applied Therapeutics Inc.
    $APLT
    12/3/2025$1.00Outperform → Market Perform
    Leerink Partners
    More analyst ratings

    $APLT
    $BPTS
    $BTMD
    $GRTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Tokman Alexander Y was granted 26,921 shares, increasing direct ownership by 36% to 101,926 units (SEC Form 4)

    4 - ENDRA Life Sciences Inc. (0001681682) (Issuer)

    3/4/26 9:48:18 PM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Financial Officer Jacroux Richard was granted 13,461 shares, increasing direct ownership by 67% to 33,461 units (SEC Form 4)

    4 - ENDRA Life Sciences Inc. (0001681682) (Issuer)

    3/4/26 9:48:01 PM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Commercial Officer Danahy Kevin Patrick exercised 5,000 shares at a strike of $1.53 and sold $118,200 worth of shares (5,000 units at $23.64) (SEC Form 4)

    4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)

    2/23/26 8:55:39 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    $APLT
    $BPTS
    $BTMD
    $GRTX
    SEC Filings

    View All

    SEC Form 10-K filed by Galera Therapeutics Inc.

    10-K - Galera Therapeutics, Inc. (0001563577) (Filer)

    3/19/26 7:15:26 AM ET
    $GRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pulse Biosciences Inc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - PULSE BIOSCIENCES, INC. (0001625101) (Filer)

    3/17/26 8:59:29 AM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    SEC Form PRE 14A filed by Medpace Holdings Inc.

    PRE 14A - Medpace Holdings, Inc. (0001668397) (Filer)

    3/16/26 5:23:12 PM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $APLT
    $BPTS
    $BTMD
    $GRTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual Meeting

    WALTHAM, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced an upcoming poster presentation at the American Association for Cancer Research (AACR) Annual Meeting, taking place from April 17-22, 2026 at the San Diego Convention Center in San Diego, California. Poster presentation details, as follows: Title: Discovery and Optimization of XTX601, a Masked Claudin 18.2-Targeting T Cell EngagerSession Category: ImmunologySession Title: T Cell Engagers 1Session Date and Time: Monday, Apr. 20, 2026, from 9:00 a.m. to 12:0

    3/17/26 4:45:00 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Recent Study Confirms Fundamental Correlation Between Severity of Obstructive Sleep Apnea and Oral Anatomy

    LITTLETON, Colo., March 17, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and healthcare services company focused on the treatment of breathing related sleep disorders and associated chronic health conditions, today announced that an a recent study published in the Journal of Clinical Medicine supports Vivos' long maintained belief that dental and facial morphology characterized by narrow palatal (upper) dental arches, high peaked palates, and recessed lower jaws were directly correlated to the prevalence and severity of obstructive sleep apnea (OSA) in adults and children. Over the past decade, Vivos-trained provider

    3/17/26 8:45:00 AM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    Pulse Biosciences Announces Strategic Alignment to Accelerate Cardiac Catheter Program Following Exceptional Long-Term AFib Clinical Data

    Pulse Biosciences, Inc. (NASDAQ:PLSE), pioneer of the novel nPulse™ platform using proprietary Nanosecond Pulsed Field Ablation (nsPFA™), today announced a new strategic alignment to prioritize and accelerate the development and future commercialization of its nPulse Cardiac Catheter Ablation System. "The European feasibility data from over 150 patients sends a definitive message," said Bob Duggan, Co-Chairman of Pulse Biosciences. "The nPulse clinical performance demonstrates a clear potential to change clinical practice for the health treatment of millions of patients. Our mission to support this program deserves our highest priority, and we are updating our capital allocation to align

    3/17/26 7:00:00 AM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    $APLT
    $BPTS
    $BTMD
    $GRTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Duggan Robert W bought $2,788,624 worth of shares (192,599 units at $14.48), increasing direct ownership by 0.41% to 47,709,140 units (SEC Form 4)

    4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)

    9/12/25 8:14:18 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    Director Shannon James Samuel bought $48,085 worth of shares (70,000 units at $0.69) (SEC Form 4)

    4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)

    6/18/25 4:57:19 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PRESIDENT AND CEO Russo Rene bought $24,680 worth of shares (36,289 units at $0.68), increasing direct ownership by 15% to 281,172 units (SEC Form 4)

    4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)

    6/18/25 4:56:47 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLT
    $BPTS
    $BTMD
    $GRTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Medpace upgraded by Barclays with a new price target

    Barclays upgraded Medpace from Underweight to Equal Weight and set a new price target of $500.00

    3/6/26 8:19:59 AM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    RBC Capital Mkts initiated coverage on Medpace with a new price target

    RBC Capital Mkts initiated coverage of Medpace with a rating of Outperform and set a new price target of $522.00

    3/3/26 8:27:50 AM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Medpace upgraded by TD Cowen with a new price target

    TD Cowen upgraded Medpace from Sell to Hold and set a new price target of $419.00

    2/18/26 7:50:53 AM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $APLT
    $BPTS
    $BTMD
    $GRTX
    Leadership Updates

    Live Leadership Updates

    View All

    Pulse Biosciences, Inc. Appoints Maria Sainz to its Board of Directors

    Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced the appointment of Maria Sainz to its Board of Directors effective as of January 9, 2026. "We are delighted to welcome Maria to our Board of Directors," said Pulse Biosciences' Co-Chairman of the Board Robert W. Duggan. "She brings an exceptionally strong track record of guiding both public and private medical device companies through growth, commercialization, viability, and scale. Her strategic and operational expertise will be invaluable as Pulse begins creating and disrupting interventional m

    1/9/26 7:00:00 AM ET
    $AVNS
    $HYPR
    $OFIX
    Industrial Specialties
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Medical/Dental Instruments

    Applied Therapeutics Reports Third Quarter 2025 Financial Results

    –   Update on regulatory strategy for govorestat for the treatment of CMT-SORD following receipt of Type C meeting minutes –   Meeting scheduled with the FDA in 4Q 2025 to discuss govorestat for the treatment of Classic Galactosemia –   New data on govorestat for the treatment of PMM2-CDG published in JIMD and presented at the 2025 ASHG Annual Meeting –   Announces Board of Directors Leadership Transition NEW YORK, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT) (the "Company"), a clinical-stage biopharmaceutical company dedicated to creating transformative treatments for rare diseases, today reported financial results for the third quarter ended September 30

    11/13/25 7:00:00 AM ET
    $APLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Catalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of Directors

    CORAL GABLES, Fla., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX) today announced the appointment of Daniel Curran, MD, to its Board of Directors. Dr. Curran is a distinguished pharmaceutical executive with over 25 years of experience spanning strategy, business development, project leadership, and development. Since March 2024, he has served as Managing Partner of Mountainfield Venture Partners, a company-creation firm. He also currently serves as Chief Executive Officer of Timberlyne Therapeutics, a clinical-stage company focused on the development and commercialization of transformational therapies for autoimmune diseases. "Da

    8/4/25 8:03:00 AM ET
    $CPRX
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLT
    $BPTS
    $BTMD
    $GRTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Applied Therapeutics Inc.

    SC 13G/A - Applied Therapeutics, Inc. (0001697532) (Subject)

    11/14/24 5:47:55 PM ET
    $APLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Xilio Therapeutics Inc.

    SC 13G/A - Xilio Therapeutics, Inc. (0001840233) (Subject)

    11/14/24 5:44:28 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Applied Therapeutics Inc.

    SC 13G/A - Applied Therapeutics, Inc. (0001697532) (Subject)

    11/14/24 4:50:26 PM ET
    $APLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLT
    $BPTS
    $BTMD
    $GRTX
    Financials

    Live finance-specific insights

    View All

    Biote Reports Fourth Quarter and Full Year 2025 Financial Results

    Executing efficiently on strategic priorities Continued salesforce expansion to capture large growth opportunity Anticipate a return to procedure revenue growth in the second half of 2026 Fourth Quarter 2025 Financial Highlights Revenue of $46.4 million Gross profit margin of 68.0% Net income of $2.6 million and diluted earnings per share attributable to biote Corp. stockholders of $0.06, compared to net income of $3.5 million and diluted earnings per share attributable to biote Corp. stockholders of $0.10 in the fourth quarter of 2024 Adjusted EBITDA1 of $11.7 million and Adjusted EBITDA margin1 of 25.2% Full Year 2025 Financial Highlights Revenue of $192.2 million

    3/11/26 4:05:00 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Biote Schedules Fourth Quarter and Full Year 2025 Financial Results Release and Conference Call

    biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading innovator advancing the healthspan of patients' lives by providing hormone replacement therapy and healthy aging solutions, today announced the Company will provide fourth quarter and full year financial results on Wednesday, March 11, 2026, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call may be accessed by dialing (844) 481-2820 (U.S. toll-free) or (412) 317-0679 (International). The live webcast of the call can be accessed using the following link: biote Corp. Fourth Quarter Earnings Call. A replay of the

    2/25/26 4:05:00 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2025 Financial Results

    Pulse Biosciences, Inc. (NASDAQ:PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced business updates and financial results for the fourth quarter and full year ended December 31, 2025. Recent Business Highlights Endocardial Catheter AF Ablation Highlighted 100% procedural success, or freedom from atrial fibrillation (AF), at 6 months and 96% procedural success at one year, of evaluable patients, following treatments with the nPulse Cardiac Catheter System in the first-in-human feasibility study which was presented as late-breaking data at the 31st Annual AF Symposium Meeting. Receiv

    2/19/26 4:05:00 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care